Inonu University, Faculty of Medicine, Department of Physiology, Malatya, Turkey.
Inonu University, Faculty of Medicine, Department of Physiology, Malatya, Turkey.
Life Sci. 2019 Sep 15;233:116698. doi: 10.1016/j.lfs.2019.116698. Epub 2019 Jul 26.
Type 1 diabetes (T1DM) is a common chronic disease in childhood. Increasing insulin resistance in puberty gives rise to higher doses of insulin usage in treatment. Of this reason new approaches in treatment are needed. Noopept researches suggest it to have anti-diabetic properties. We tried to determine the effects of noopept on pubertal diabetes.
The research was made with 60 prepubertal, 28 day-old, male, Sprague Dawley rats. The rats were divided into randomised 6 groups (n = 10/group). i) Control, ii) Diabetes Control, iii) Noopept Control, iv) Diabetes + Noopept, v) Diabetes + Insulin, vi) Diabetes + Insulin + Noopept. T1DM model was induced by streptozotocin on postnatal 28th day. 0.5 mg/kg noopept and 1 IU insulin were administered intraperitoneally for 14 days. Blood glucose and body weight measurements, puberty follow-up and MWM tests were performed. Hippocampus, hypothalamus and testis were evaluated histologically. Hypothalamic GnRH and kisspeptin were studied immunohistochemically. Serum LH, FSH and insulin, hippocampal homogenate NGF and BDNF levels were determined by ELISA.
Delayed puberty was normalized by noopept (p < 0.05). Blood glucose levels were lower in noopept-administered diabetic groups (p < 0.05). Noopept decreased HOMA-IR in insulin administered diabetic group (p < 0.05). Number of degenerated cells in hippocampus and testis were higher in diabetes control group when compared with other groups (p < 0.05). GnRH immunoreactivity in Diabetes + Noopept group was increased when compared to insulin + noopept group (p = 0.018). There was no difference in kisspeptin, serum LH, FSH, hippocampal NGF-BDNF levels and spatial learning assessment among groups (p > 0.05).
Noopept may have positive effect in treatment of pubertal diabetes.
1 型糖尿病（T1DM）是儿童期常见的慢性疾病。青春期胰岛素抵抗的增加导致治疗中需要更高剂量的胰岛素。出于这个原因，需要新的治疗方法。Noopept 的研究表明它具有抗糖尿病作用。我们试图确定 Noopept 对青春期糖尿病的影响。
该研究使用了 60 只未成熟、28 天大、雄性 Sprague Dawley 大鼠。将大鼠随机分为 6 组（每组 n=10）。i）对照组，ii）糖尿病对照组，iii）Noopept 对照组，iv）糖尿病+Noopept 组，v）糖尿病+胰岛素组，vi）糖尿病+胰岛素+Noopept 组。T1DM 模型在出生后第 28 天通过链脲佐菌素诱导。在 14 天内腹膜内给予 0.5mg/kg Noopept 和 1IU 胰岛素。进行血糖和体重测量、青春期随访和 MWM 测试。评估海马体、下丘脑和睾丸的组织学。免疫组织化学研究下丘脑 GnRH 和 kisspeptin。通过 ELISA 测定血清 LH、FSH 和胰岛素、海马匀浆 NGF 和 BDNF 水平。
Noopept 使青春期延迟正常化（p<0.05）。给予 Noopept 的糖尿病组血糖水平较低（p<0.05）。Noopept 降低了胰岛素给予的糖尿病组的 HOMA-IR（p<0.05）。与其他组相比，糖尿病对照组海马体和睾丸中退化细胞的数量更高（p<0.05）。与胰岛素+Noopept 组相比，糖尿病+Noopept 组 GnRH 免疫反应性增加（p=0.018）。各组间 kisspeptin、血清 LH、FSH、海马 NGF-BDNF 水平和空间学习评估无差异（p>0.05）。
Noopept 可能对青春期糖尿病的治疗有积极作用。
